Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • RFK Jr.’s Future
  • Melanoma Drug
  • Charity Care Gap
  • Search for New FDA Chief

WHAT'S NEW

  • RFK Jr.'s Future
  • Melanoma Drug
  • Charity Care Gap
  • Search for New FDA Chief

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Sep 21 2021

Full Issue

Drugmakers That Raise Prices Too Fast Face Penalties Under Broader Senate Plan

Stat reports a Senate committee signaled it is willing to expand a proposal to penalize pharmaceutical companies that hike drug prices at a quicker rate than inflation. Other news from Capitol Hill covers the Patent Office's role in generics and the National Academies of Sciences, Engineering and Medicine.

Stat: Senate Broadens Its Plans To Penalize Pharma For Hiking Drug Prices

A key Senate panel is expanding its plans to punish drug makers that hike prices faster than inflation, according to an internal Senate document described to STAT. The policy, which is being considered as part of Democrats’ efforts to include drug pricing reforms in a sweeping government spending package, has the potential to change the way drug makers set launch prices for drugs, and how they choose to adjust prices over time. (Cohrs, 9/20)

Stat: U.S. Lawmakers Accuse Patent Office Of Weakening Challenges And Allowing Drug Prices To Rise 

A bipartisan group of lawmakers has accused the U.S. Patent & Trademark Office of “weakening” the system for challenging patents and, as a result, encouraging abuses by drug makers that seek to thwart the availability of lower-cost generic medicines. At issue is the inter partes review, or IPR, which went into effect in 2012 as a result of the America Invents Act. This type of patent challenge, which is heard by the Patent and Trials Appeal Board, was intended to provide an easier and faster alternative to patent infringement lawsuits filed in federal courts. For this reason, the IPR process has irked brand-name pharmaceutical companies. (Silverman, 9/20)

KHN: Congress Cites KHN Investigation In Probe Of National Academies 

The House Committee on Oversight and Reform is requesting a ream of documents from the prestigious National Academies of Sciences, Engineering and Medicine, spurred by a recent KHN investigation that revealed deep ties between pharmaceutical companies and two members of a committee that took a pharma-friendly stance in a recent report on drug waste. The House probe, led by Democratic Reps. Raja Krishnamoorthi and Katie Porter, focuses on conflicts of interest held by members of a committee currently reviewing a life-or-death matter: U.S. organ donation and distribution policy. A panel member recently resigned after accepting a consulting job that apparently created a conflict of interest. House members are asking NASEM to provide conflict-of-interest disclosure forms for all members of the committee. (Jewett and Aleccia, 9/21)

And lawmakers continue to scratch and claw at the infrastructure bill —

The Washington Post: Democrats Once Sweeping Agenda On Immigration, Voting Rights, Police Reform And Minimum Wage Continues To Shrink

President Biden’s governing agenda is at risk of unraveling on Capitol Hill after a mounting series of delays, clashes and setbacks that have sapped momentum from an ambitious and intricate push to deliver on long-standing Democratic policy priorities. An overhaul of the nation’s voting laws has been blocked by Republicans. An effort to strike a bipartisan deal on police reforms has lost all momentum. A sweeping immigration plan to provide a path to legal residency for millions of undocumented immigrants is now all but dead. (DeBonis, Sullivan and Sacchetti, 9/20)

Stateline: States Use Hurricane Ida Damage To Push Infrastructure Bill

Pointing to stark pictures of inundated buildings and washed-out cars from Hurricane Ida, state and city officials are pressing Congress to pass a $1 trillion infrastructure bill. At least 67 people died across eight states, communities were plunged into darkness for weeks while repairs to the electrical grid plodded along, and calls for help went unanswered because of lack of internet access. The storm prompted demands for more flood mitigation and enhanced building construction to help communities better withstand storms and prevent future Ida-level damage. It also illustrated the need for the expansion of broadband, rural advocates say. (Povich, 9/20)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 15
  • Thursday, May 14
  • Wednesday, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF